[go: up one dir, main page]

WO2004069990A3 - Oligomeric compounds for the modulation of thioredoxin expression - Google Patents

Oligomeric compounds for the modulation of thioredoxin expression Download PDF

Info

Publication number
WO2004069990A3
WO2004069990A3 PCT/DK2004/000095 DK2004000095W WO2004069990A3 WO 2004069990 A3 WO2004069990 A3 WO 2004069990A3 DK 2004000095 W DK2004000095 W DK 2004000095W WO 2004069990 A3 WO2004069990 A3 WO 2004069990A3
Authority
WO
WIPO (PCT)
Prior art keywords
trx
expression
oligonucleotides
modulation
lung
Prior art date
Application number
PCT/DK2004/000095
Other languages
French (fr)
Other versions
WO2004069990A2 (en
Inventor
Bo Hansen
Charlotte Albaek Thrue
Kamille Dumong Petersen
Majken Westergaard
Margit Wissenbach
Original Assignee
Santaris Pharma As
Bo Hansen
Charlotte Albaek Thrue
Kamille Dumong Petersen
Majken Westergaard
Margit Wissenbach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma As, Bo Hansen, Charlotte Albaek Thrue, Kamille Dumong Petersen, Majken Westergaard, Margit Wissenbach filed Critical Santaris Pharma As
Priority to JP2006501523A priority Critical patent/JP2006518999A/en
Priority to CA002515554A priority patent/CA2515554A1/en
Priority to EP04709581A priority patent/EP1592794A2/en
Priority to AU2004209597A priority patent/AU2004209597A1/en
Publication of WO2004069990A2 publication Critical patent/WO2004069990A2/en
Publication of WO2004069990A3 publication Critical patent/WO2004069990A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)

Abstract

Oligonucleotides directed against the TRX gene are provided for modulating the expression of TRX. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the TRX. Methods of using these compounds for modulation of TRX expression and for the treatment of diseases associated with either overexpression of TRX, expression of mutated TRX or both are provided. Examples of diseases are cancer such as lung, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.
PCT/DK2004/000095 2003-02-10 2004-02-10 Oligomeric compounds for the modulation of thioredoxin expression WO2004069990A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006501523A JP2006518999A (en) 2003-02-10 2004-02-10 Oligomeric compounds for modification of thioredoxin expression
CA002515554A CA2515554A1 (en) 2003-02-10 2004-02-10 Oligomeric compounds for the modulation of thioredoxin expression
EP04709581A EP1592794A2 (en) 2003-02-10 2004-02-10 Oligomeric compounds for the modulation of thioredoxin expression
AU2004209597A AU2004209597A1 (en) 2003-02-10 2004-02-10 Oligomeric compounds for the modulation of thioredoxin expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300188 2003-02-10
DKPA200300188 2003-02-10

Publications (2)

Publication Number Publication Date
WO2004069990A2 WO2004069990A2 (en) 2004-08-19
WO2004069990A3 true WO2004069990A3 (en) 2004-09-16

Family

ID=32842639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000095 WO2004069990A2 (en) 2003-02-10 2004-02-10 Oligomeric compounds for the modulation of thioredoxin expression

Country Status (5)

Country Link
EP (1) EP1592794A2 (en)
JP (1) JP2006518999A (en)
AU (1) AU2004209597A1 (en)
CA (1) CA2515554A1 (en)
WO (1) WO2004069990A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2456990T3 (en) * 2007-11-26 2014-04-24 Santaris Pharma A/S LNA-based antagonists targeting the androgen receptor
JP6429264B2 (en) * 2013-11-12 2018-11-28 学校法人東京理科大学 Boranophosphate compounds and nucleic acid oligomers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038963A1 (en) * 1998-01-30 1999-08-05 Genesense Technologies, Inc. Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
WO2001048190A2 (en) * 1999-12-23 2001-07-05 Exiqon A/S Therapeutic uses of lna-modified oligonucleotides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038963A1 (en) * 1998-01-30 1999-08-05 Genesense Technologies, Inc. Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
WO2001048190A2 (en) * 1999-12-23 2001-07-05 Exiqon A/S Therapeutic uses of lna-modified oligonucleotides

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ALTMANN K.-H. ET AL.: "NOVEL CHEMISTRY", 1998, APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY; STEIN C.A. AND KRIEG A.M. EDS. WILEY-LISS INC., US, ISBN: 0-471-17279-0, XP002119324 *
ANDOH T. ET AL.: "The roles of Thioredoxin in protection against oxidative stress-induced apoptosis in SH-SY5Y cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 12, 22 March 2002 (2002-03-22), pages 9655 - 0660, XP002290398 *
BIESSEN E.A.L. ET AL.: "Design of a targeted peptide nucleic acid prodrug to inhibit hepatic human microsomal triglyceride transfer protein expression in hepatocytes", BIOCONJUGATE CHEMISTRY, vol. 13, 2002, pages 295 - 302, XP002290397 *
BRAASCH D.A . ET AL.: "Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA", CHEMISTRY AND BIOLOGY, vol. 8, no. 1, January 2001 (2001-01-01), pages 1 - 7, XP002255827, ISSN: 1074-5521 *
BRAASCH D.A. ET AL.: "Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design", NUCLEIC ACIDS RESEARCH, vol. 30, no. 23, 2002, pages 5160 - 5167, XP002290400 *
FLUITER K. ET AL.: "In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides", NUCLEIC ACIDS RESEARCH, vol. 31, no. 3, 1 February 2003 (2003-02-01), pages 953 - 962, XP002290401 *
HORI K. ET AL.: "Expression of Adult T Cell Leukemia-derived Factor / Human Thioredoxin in human gliomas", MIE MEDICAL JOURNAL, vol. 44, no. 1, 1994, pages 19 - 24, XP008033406 *
KOJI MORITA ET AL.: "2'-O,4'-C-ethylene-bridged nucleic acid (ENA): highly nuclease resistant and thermodinamically stable oligonucleotides for antisense drug", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 12, 2002, pages 73 - 76, XP002290399 *
KURRECK J. ET AL.: "Design of antisense oligonucleotides stabilized by locked nucleic acids", NUCLEIC ACIDS RESEARCH, vol. 30, no. 9, 1 May 2002 (2002-05-01), pages 1911 - 1918, XP002281375, ISSN: 0305-1048 *
OERUM H. ET AL.: "Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development", CURRENT OPINION IN MOLECULAR THERAPEUTICS, vol. 3, no. 3, June 2001 (2001-06-01), pages 239 - 243, XP001179829, ISSN: 1464-8431 *
RAIT A.S. ET AL.: "Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer", CANCER GENE THERAPY, vol. 8, no. 10, 2001, pages 728 - 739, XP008005112, ISSN: 0929-1903 *
SAITOH M ET AL: "Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1", EMBO JOURNAL, vol. 17, no. 9, 1 May 1998 (1998-05-01), pages 2596 - 2606, XP002106020, ISSN: 0261-4189 *

Also Published As

Publication number Publication date
EP1592794A2 (en) 2005-11-09
WO2004069990A2 (en) 2004-08-19
AU2004209597A1 (en) 2004-08-19
JP2006518999A (en) 2006-08-24
CA2515554A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
WO2004069991A3 (en) Oligomeric compounds for the modulation of survivin expression
WO2004069992A3 (en) Oligomeric compounds for the modulation of ras expression
WO2007031081A3 (en) RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-Bl00 EXPRESSION
WO2007031091A3 (en) Rna antagonist compounds for the modulation of p21 ras expression
WO2004110345A8 (en) Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
WO2005118825A3 (en) Chimeric adenoviruses for use in cancer treatment
WO2005005599A3 (en) Modulation of c-reactive protein expression
WO2000022130A3 (en) Metastatic breast and colon cancer regulated genes
WO2005000201A3 (en) Modulation of apolipoprotein (a) expression
EP1632499A3 (en) Gene sequences amplified in tumours and their diagnostic uses
WO2002029086A3 (en) Nucleic acid sequences differentially expressed in cancer tissue
WO2000053755A3 (en) Compositions and methods for the treatment of tumor
WO2008097466A3 (en) Metastasis specific splice variants of mena and uses thereof in diagnosis, prognosis and treatment of tumors
WO2006026485A3 (en) Modulation of hif1-beta expression
WO2012018613A3 (en) Genetic make-up modifies cancer outcome
WO2004048534A3 (en) Modulation of cytokine-inducible kinase expression
WO2007092944A3 (en) Compositions and methods involving gene therapy and proteasome modulation
WO2007002746A3 (en) Molecular/genetic aberrations in surgical margins of resected pancreatic cancer represents neoplastic disease that correlates with disease outcome
WO2007062380A3 (en) Modulation of eif4e-bp2 expression
WO2004009024A3 (en) Modulation of protein kinase c-iota expression
EP1634892A3 (en) Composition and methods for the diagnosis of tumours
WO2004069990A3 (en) Oligomeric compounds for the modulation of thioredoxin expression
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
PT2066790E (en) Galactosyltransferase
WO2005006958A8 (en) Modulation of ceacam1 expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004209597

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2515554

Country of ref document: CA

Ref document number: 2006501523

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004209597

Country of ref document: AU

Date of ref document: 20040210

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2004709581

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004209597

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004709581

Country of ref document: EP